Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
SNSS something brewing!
Pharmaceutical up %30 on friday had twice as many buys than sells. Biggest volume day since 4 years ago when it IPOd. Increasing volume past two weeks!
SNSS has something going on.
Pharmaceutical up %30 on friday had twice as many buys than sells. Biggest volume day since 4 years ago when it IPOd. Increasing volume past two weeks!
I want to see a 4 close!
Looks good!
I still have my big chunk of shares waiting more patiently than I thought! LOL
SNSS
will be one of the highest volume days in 3 years! Could be the Highest, the way it is trading today!
SNSS
will be one of the highest volume days in 3 years! Could be the Highest, the way it is trading today!
SNSS
will be one of the highest volume days in 3 years! Could be the Highest, the way it is trading today!
will be one of the highest volume days in 3 years! Could be the Highest, the way it is trading today!
SNSS Has had major buying lately. Going to make some Kaboomage!
SNSS Getting some nice volume PPS LOVE!
yep jiggy might be an understatement!
LOL
SNSS getting the VOLUME love. Chart looks great too. This is a gem to watch!
todays trades bigger blocks than yesterday!
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM D
Notice of Exempt Offering of Securities
OMB APPROVAL
OMB Number: 3235-0076
Expires: September 30, 2008
Estimated average burden
hours per response: 4.00
1. Issuer's Identity
CIK (Filer ID Number) Previous Names
None
Entity Type
0001061027
MOSAIC PHARMACEUTICALS INC
X Corporation
Limited Partnership
Limited Liability Company
General Partnership
Business Trust
Other
Name of Issuer
SUNESIS PHARMACEUTICALS INC
Jurisdiction of Incorporation/Organization
DE
Year of Incorporation/Organization
X Over Five Years Ago
Within Last Five Years (Specify Year)
Yet to Be Formed
2. Principal Place of Business and Contact Information
Name of Issuer
SUNESIS PHARMACEUTICALS INC
Street Address 1 Street Address 2
395 OYSTER POINT BOULEVARD SUITE 400
City State/Province/Country ZIP/PostalCode Phone Number of Issuer
SOUTH SAN FRANCISCO CA 94080 650-266-3500
3. Related Persons
Last Name First Name Middle Name
Swisher Daniel N., Jr.
Street Address 1 Street Address 2
395 Oyster Point Boulevard, Suite 400
City State/Province/Country ZIP/PostalCode
South San Francisco CA 94080
Relationship: X Executive Officer X Director Promoter
Clarification of Response (if Necessary):
Last Name First Name Middle Name
Bjerholt Eric H.
Street Address 1 Street Address 2
395 Oyster Point Boulevard, Suite 400
City State/Province/Country ZIP/PostalCode
South San Francisco CA 94080
Relationship: X Executive Officer Director Promoter
Clarification of Response (if Necessary):
Last Name First Name Middle Name
Ketchum Steven B.
Street Address 1 Street Address 2
395 Oyster Point Boulevard, Suite 400
City State/Province/Country ZIP/PostalCode
South San Francisco CA 94080
Relationship: X Executive Officer Director Promoter
Clarification of Response (if Necessary):
Last Name First Name Middle Name
Fust Matthew K.
Street Address 1 Street Address 2
c/o Onyx Pharmaceuticals, Inc. 2100 Powell Street
City State/Province/Country ZIP/PostalCode
Emeryville CA 94608
Relationship: Executive Officer X Director Promoter
Clarification of Response (if Necessary):
Last Name First Name Middle Name
Hurwitz Ed
Street Address 1 Street Address 2
c/o Sunesis Pharmaceuticals, Inc. 395 Oyster Point Boulevard, Suite 400
City State/Province/Country ZIP/PostalCode
South San Francisco CA 94080
Relationship: Executive Officer X Director Promoter
Clarification of Response (if Necessary):
Last Name First Name Middle Name
Misfeldt Dayton
Street Address 1 Street Address 2
c/o Bay City Capital LLC 750 Battery Street, Suite 400
City State/Province/Country ZIP/PostalCode
San Francisco CA 94111
Relationship: Executive Officer X Director Promoter
Clarification of Response (if Necessary):
Last Name First Name Middle Name
Pearce Homer L.
Street Address 1 Street Address 2
c/o Sunesis Pharmaceuticals, Inc. 395 Oyster Point Boulevard, Suite 400
City State/Province/Country ZIP/PostalCode
South San Francisco CA 94080
Relationship: Executive Officer X Director Promoter
Clarification of Response (if Necessary):
Last Name First Name Middle Name
Stump David C.
Street Address 1 Street Address 2
c/o Human Genome Sciences, Inc. 14200 Shady Grove Road
City State/Province/Country ZIP/PostalCode
Rockville MD 20850
Relationship: Executive Officer X Director Promoter
Clarification of Response (if Necessary):
Last Name First Name Middle Name
Young James W.
Street Address 1 Street Address 2
c/o 5AM Ventures 2200 Sand Hill Road
City State/Province/Country ZIP/PostalCode
Menlo Park CA 94025
Relationship: Executive Officer X Director Promoter
Clarification of Response (if Necessary):
4. Industry Group
Agriculture
Banking & Financial Services
Commercial Banking
Insurance
Investing
Investment Banking
Pooled Investment Fund
Is the issuer registered as
an investment company under
the Investment Company
Act of 1940?
Yes No
Other Banking & Financial Services
Business Services
Energy
Coal Mining
Electric Utilities
Energy Conservation
Environmental Services
Oil & Gas
Other Energy
Health Care
Biotechnology
Health Insurance
Hospitals & Physicians
X Pharmaceuticals
Other Health Care
Manufacturing
Real Estate
Commercial
Construction
REITS & Finance
Residential
Other Real Estate
Retailing
Restaurants
Technology
Computers
Telecommunications
Other Technology
Travel
Airlines & Airports
Lodging & Conventions
Tourism & Travel Services
Other Travel
Other
5. Issuer Size
Revenue Range Aggregate Net Asset Value Range
No Revenues No Aggregate Net Asset Value
$1 - $1,000,000 $1 - $5,000,000
X $1,000,001 - $5,000,000 $5,000,001 - $25,000,000
$5,000,001 - $25,000,000 $25,000,001 - $50,000,000
$25,000,001 - $100,000,000 $50,000,001 - $100,000,000
Over $100,000,000 Over $100,000,000
Decline to Disclose Decline to Disclose
Not Applicable Not Applicable
6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)
Rule 504(b)(1) (not (i), (ii) or (iii)) Rule 505
Rule 504 (b)(1)(i) X Rule 506
Rule 504 (b)(1)(ii) Securities Act Section 4(6)
Rule 504 (b)(1)(iii) Investment Company Act Section 3(c)
Section 3(c)(1) Section 3(c)(9)
Section 3(c)(2) Section 3(c)(10)
Section 3(c)(3) Section 3(c)(11)
Section 3(c)(4) Section 3(c)(12)
Section 3(c)(5) Section 3(c)(13)
Section 3(c)(6) Section 3(c)(14)
Section 3(c)(7)
7. Type of Filing
X New Notice Date of First Sale 2009-04-03 First Sale Yet to Occur
Amendment
8. Duration of Offering
Does the Issuer intend this offering to last more than one year?
Yes X No
9. Type(s) of Securities Offered (select all that apply)
X Equity Pooled Investment Fund Interests
Debt Tenant-in-Common Securities
X Option, Warrant or Other Right to Acquire Another Security Mineral Property Securities
Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security Other (describe)
10. Business Combination Transaction
Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?
Yes X No
Clarification of Response (if Necessary):
11. Minimum Investment
Minimum investment accepted from any outside investor $0 USD
12. Sales Compensation
Recipient
Recipient CRD Number None
Jefferies & Company, Inc. 2347
(Associated) Broker or Dealer X None
(Associated) Broker or Dealer CRD Number X None
None None
Street Address 1 Street Address 2
520 Madison Avenue, 12th Floor
City State/Province/Country ZIP/Postal Code
New York NY 10022
State(s) of Solicitation All States
CA
CT
DC
FL
MD
MA
NJ
NY
NC
PA
WA
13. Offering and Sales Amounts
Total Offering Amount $15,000,000 USD
or Indefinite
Total Amount Sold $10,000,000 USD
Total Remaining to be Sold $5,000,000 USD
or Indefinite
Clarification of Response (if Necessary):
Private placement of the sale up to $15.0 million of units consisting of Series A Preferred Stock and warrants to purchase common stock.
14. Investors
Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.
Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
18
15. Sales Commissions & Finder's Fees Expenses
Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.
Sales Commissions $0 USD
Estimate
Finders' Fees $588,000 USD
Estimate
Clarification of Response (if Necessary):
*Placement Agent Fees paid in this offering to Recipient listed in Item 12.
16. Use of Proceeds
Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.
$0 USD
Estimate
Clarification of Response (if Necessary):
Proceeds from the private placement are to be used for working capital and other general corporate purposes.
Signature and Submission
Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.
Terms of Submission
In submitting this notice, each issuer named above is:
* Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
* Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
* Certifying that, if the issuer is claiming a Rule 505 exemption, the issuer is not disqualified from relying on Rule 505 for one of the reasons stated in Rule 505(b)(2)(iii).
Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.
For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.
Issuer Signature Name of Signer Title Date
SUNESIS PHARMACEUTICALS INC Eric H. Bjerkholt Eric Bjerkholt SVP Corporate Development & Finance, Chief Financial Officer 2009-04-16
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.
* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.
SYNJ NEWS
Syndication Inc. Engages the 'Rossi Law Firm' to Point its PINNACLE ENERGY PROJECT; Reminds Shareholders of the 5% Dividend Record Date as of April 29th 2009
* Friday April 17, 2009, 8:50 am EDT
DAMASCUS, Md., April 16 /PRNewswire/ -- Syndication Inc. (Pink Sheets: SYNJ - News) reported that it has engaged the 'Rossi Law Firm' to handle the project developments of its Pinnacle Energy Division. Mr. Rossi is a Principal of the firm with over 20 years of experience at securities law, international legal affairs and direct investment. Mr. Rossi provides integrated strategies for managing the most difficult of structural issues including securities offering materials, SEC filings to go public, anti-takeover strategies, financial presentations and capital raising plans, annual shareholder meeting preparation, valuations and corporate governance. Mr. Rossi is also the founder and Principle of the 'Capital Keys' law firm located in Washington DC. 'Capital Keys' works closely with the White House, the Congress, Federal and State Agencies (State, Treasury, Energy, Homeland Security, Commerce, Health and Human Services, Transportation, Interior, Education, FDA, SEC, FCC, EPA), the Diplomatic Community, the Leadership of the Fortune 500, Investment Firms, and the Media helping its clients tackle hurdles, realize exponential growth and thrive, www.capitalkeys.com.
In earlier news releases Syndication indicated that it intended to take full advantage of the government financing currently being offered under the Obama administration. To that effort the CEO has worked very diligently through the Pickens Energy Program and other avenues to place Syndication at the crossroads of a massive new technological revolution and to equip it with a political presence he believes will play a required role in the application process related to this type of funding. "If the Company is going to avail itself of these opportunities, specifically in the arena of government funding, it will need the 'political cache' to do it, and now our team is together. We have the project and now we have the team," said Sorrentino, the CEO of Syndication Inc.
The CEO would like to remind the shareholders of the pending Record Date of the 5% dividend that is to be paid on all shares owned as of the record date 'APRIL 29th 2009'. "The 'Record Date,' (April 29th 2009), might be a good day to own our stock but, I'm not allowed to recommend," said Sorrentino the CEO of Syndication Inc.
"The 'Record Date,' (April 29th 2009), might be a good day to own our stock but, I'm not allowed to recommend," said Sorrentino the CEO of Syndication Inc.
NICE!
Looks like the charts are setting up nice! Accumulation has been increasing. Volume has been increasing hugely!
what was the buys vs sells. I see the accumulation is building up huge on the chart...
ur welcome did you grab any before close?
BSDM 11 MIL FLOAT and FDA approval
11 million float could be the answer!
LOL I dont know but its harder than heck to get shares....
its trading tight!!!!!!!!!
50 MA .00021
100 MA .00024
200 MA .18551
50 MA and 100 MA is getting ready to crossover!
yeah actually I did a little this weekend, I need to look again but I think they will release fins soon. They submitted a delayed filing, which they normally do.
.83 up!
SettlementDate ShortInterestAvg DailyShareVolume Days To Cover
3/31/2009 70,235,368 37,633,506 1.866299
3/13/2009 64,677,627 6,319,712 10.234268
2/27/2009 63,563,747 9,061,264 7.014887
2/13/2009 56,181,736 8,821,389 6.368808
1/30/2009 52,597,782 6,668,152 7.887910
1/15/2009 53,396,875 12,384,106 4.311726
12/31/2008 54,636,448 12,676,877 4.309930
12/15/2008 56,643,645 26,024,858 2.176521
11/28/2008 57,790,391 25,354,255 2.279317
11/14/2008 54,991,755 13,583,457 4.048436
10/31/2008 55,761,457 25,066,442 2.224546
10/15/2008 64,926,616 44,331,915 1.464557
9/30/2008 70,555,729 129,284,564 1.000000
9/15/2008 142,087,613 145,432,775 1.000000
8/29/2008 158,460,612 151,354,581 1.046950
8/15/2008 118,608,547 49,666,582 2.388096
7/31/2008 119,388,354 92,434,748 1.291596
7/15/2008 105,884,915 133,641,898 1.000000
6/30/2008 82,804,409 12,448,517 6.651749
6/13/2008 77,348,995 10,683,462 7.240068
5/30/2008 67,824,907 7,362,943 9.211657
5/15/2008 63,174,899 12,306,468 5.133471
4/30/2008 53,188,428 9,179,560 5.794224
4/15/2008 51,192,019 13,277,947 3.855417
huge buy EOD @ .77
see it happening by WED
FRE looks ready to boogie!
Although all authors completed the disclosure declaration, the following authors or their immediate family members indicated a financial interest. No conflict exists for drugs or devices used in a study if they are not being evaluated as part of the investigation. For a detailed description of the disclosure categories, or for more information about ASCO's conflict of interest policy, please refer to the Author Disclosure Declaration and the Disclosures of Potential Conflicts of Interest section in Information for Contributors.
Authors Employment Leadership Consultant Stock Honoraria Research Funds Testimony Other
Michael Millward Sanofi-Aventis (A)
Robert Conry Genta (A)
Martin Gore Genta (B)
Ronald DeConti Genta (A)
Evan M. Hersh Genta (B)
John M. Kirkwood Genta (B)
Frank G. Haluska Genta (B)
Dollar Amount Codes (A) < $10,000 (B) $10,000-$99,999 (C) ≥ $100,000 (N/R) Not Required
http://jco.ascopubs.org/cgi/content/full/24/29/4738
Yes, thanks for the annotations!
Stock Resistance Levels : 0.181, 0.200, 0.214, 0.231, 0.510.
Stock Support levels : 0.175, 0.175, 0.173, 0.169, 0.169, 0.165, 0.162, 0.161, 0.158, 0.150, 0.120
I am not sure why it says .51?
http://www.thestocksprofit.com/stu/660415-sg-meridian-resource/